Skip to main content

Advertisement

Table 3 Clinical outcomes after trabectedin therapy

From: Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group

Pt no. Best RECIST response PFS (months) Progression OS (months) Status at last follow-up GMI = TTP2/TTP1
TTP1 (months) TTP2 (months) GMI
1 SD 11.7 N 11.7 Alive 4.9 - -
2 SD 11.6 Y 29.2 Alive 5.6 11.6 2.07
3 SD 3.8 Y 9.1 Dead 1.9 3.8 2.02
4 SD 14.6 Y 22.3 Dead 12.6 14.6 1.16
5 SD 30.9 N 30.8 Alive 7.1 - -
6 SD 11.0 Y 20.9 Alive 3.1 11.0 3.61
7 PD 1.9 Y 7.0 Dead 18.7 1.9 0.11
8 PR 7.5 Y 23.4 Dead 5.1 7.5 1.49
9 PD 2.0 Y 11.1 Dead 7.7 2.0 0.26
10 SD 15.2 Y 17.7 Dead 25.3 15.2 0.6
11 SD 12.3 Y 74.2 Alive 3.0 12.3 4.12
Median   11.6   22.3   5.6 11.6 1.49
  1. SD stable disease, PR partial response, PD progressive disease, GMI growth modulation index, TTP1 time to progression with the prior last-line treatment, TTP2 time to progression with trabectedin